, Tracking Stock Market Picks
Enter Symbol:
Sciclone Pharmaceuticals, Inc. (SCLN) [hlAlert]

Mkt Outperform
up 342.04 %

Sciclone Pharmaceuticals, Inc. (SCLN) rated Mkt Outperform with price target $5 by Rodman & Renshaw

Posted on: Thursday,  May 21, 2009  10:25 AM ET by Rodman & Renshaw

Rodman & Renshaw rated Mkt Outperform Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) on 05/21/2009, when the stock price was $1.76.
Since then, Sciclone Pharmaceuticals, Inc. has gained 342.05% as of 01/05/2016's recent price of $7.78.
If you would have followed this Rodman & Renshaw's recommendation on SCLN, you would have gained 342.04% of your investment in 2420 days.

Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.

Rodman & Renshaw is a full-service investment bank dedicated to providing investment banking services to companies that have significant recurring capital needs due to their growth and development strategies. We also provide research and sales and trading services to institutional investor clients that focus on such companies. Since 2003, Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/21/2009 10:25 AM Buy
1.76 5.00
as of 12/31/2009
1 Week up  62.65 %
1 Month up  83.17 %
3 Months down  -7.76 %
1 YTD up  122.72 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy